Breast cancer classification

Metastatic breast cancer's Trojan horse

Retrieved on: 
Wednesday, July 26, 2023
Breast cancer classification, Therapy, Cancer, Research, Lymph, Assistant, Cancer of unknown primary origin, SPRING, Beyaz, CSHL, MHC-II, Immune system, Coffee, Mouse, Hospital, Cold Spring Harbor Laboratory, Lymph node, Massachusetts General Hospital, Metastasis, Breast cancer, Disease, Vaccine, Medical imaging, Dietary supplement

But somehow, lymph nodes are also the first stop for most metastatic cancers.

Key Points: 
  • But somehow, lymph nodes are also the first stop for most metastatic cancers.
  • They found that breast cancer cells trick the immune system with help from a molecule called MHC-II.
  • "For example, in the gut, we see the opposite of what's happening in breast cancer," Beyaz explains.
  • Over 300,000 people in the U.S. will be diagnosed with breast cancer this year alone.

Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Retrieved on: 
Thursday, December 8, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Gastric varices, Esaxerenone, Tmax, Drug discovery, Cancer, Breast cancer classification, Anemia, EXEL, COVID-19, Breast, Hypertension, Pharmacokinetics, S&P, Children's Oncology Group, Fatigue, Daiichi Sankyo, Clinical trial, Standard, Pancreatic cancer, CST, Security (finance), Midcap, Ascites, Hypokalemia, Learning, Genetics, Eastern Cooperative Oncology Group, Diarrhea, Neoplasm, Prostate, Breast cancer, Hand, Absorption, Clinical research, Liposarcoma, Sarcoma, Medical Affairs Bureau, Genentech, Biomarker, Patient, Response evaluation criteria in solid tumors, Nausea, RECIST, Vomiting, Cell death, Safety, CDK7, Hyperkalemia, Pharmaceutical industry, Medical imaging, Kerosene, Limited, Exelixis

With the initial dose-escalation results now in hand, I am excited to explore further in the QUARTZ-101 trial how XL102 may benefit patients with advanced solid tumors who have exhausted treatment options.

Key Points: 
  • With the initial dose-escalation results now in hand, I am excited to explore further in the QUARTZ-101 trial how XL102 may benefit patients with advanced solid tumors who have exhausted treatment options.
  • QUARTZ-101 is enrolling patients with solid tumors that are confirmed to be inoperable, locally advanced, metastatic or recurrent.
  • The most common types of cancer for patients enrolled were hormone receptor-positive breast cancer (n=12), pancreatic cancer (n=3) and sarcoma (n=3).
  • Exelixis, the Exelixis logo, CABOMETYX and COMETRIQ are registered U.S. trademarks of Exelixis.

Goodness Growth Holdings Celebrates the Life and Legacy of Dr. Jay Westwater with Special Event

Retrieved on: 
Tuesday, December 6, 2022
Aromatase, Plant, MD, Life, Growth, IP, CSE, Medical cannabis, AIMSS, Patient, Cancer, Cancer pain, Breast cancer classification, Science, Research, Breast cancer, Woman, Quality of life, Emergency department, Cannabis, Medical device, United Hospital, Produce

MINNEAPOLIS, Minn., Dec. 6, 2022 /PRNewswire/ -- Goodness Growth Holdings, Inc. ("Goodness Growth" or the "Company") (CSE: GDNS; OTCQX: GDNSF), a physician-led, science-focused cannabis company and IP developer, today announced that it celebrated the life and legacy of Dr. Jay Westwater and the continued advancement of research into cannabis and cancer with a special event on Thursday, Dec. 1.

Key Points: 
  • At the Dec. 1 event, members of Dr. Westwater's family joined representatives from Goodness Growth and other community participants to celebrate his life and the impact he had on his patients and the greater Minneapolis community.
  • Representatives from the Minnesota Office of Medical Cannabis and Dr. Westwater's former coworkers from United Hospital in St. Paul also attended.
  • Goodness Growth also launched its new "Dr. Westwater" brand, a line of topical cannabis products named in honor of Dr. Westwater, at the event.
  • Goodness Growth Holdings, Inc., is a physician-led, science-focused holding company whose mission is to bring the power of plants to the world.

Lilly Announces Updated Data from the Verzenio® (abemaciclib) Phase 3 monarchE Trial Presented at SABCS and Simultaneously Published in The Lancet Oncology

Retrieved on: 
Tuesday, December 6, 2022
The Lancet, Monarch butterfly migration, Recurrence, Cohort, Eli Lilly and Company, EBC, Ki-67, Patient, ET, Royal Marsden Hospital, NYSE, Breast cancer, Disease, Breast cancer classification, ALN, NHS foundation trust, Woman, Nominal interest rate, Death, ITT, The Royal Marsden NHS Foundation Trust, Risk, Pharmaceutical industry, Abemaciclib

INDIANAPOLIS, Dec. 6, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated results from the pivotal Phase 3 monarchE trial of adjuvant Verzenio® (abemaciclib) in combination with standard endocrine therapy (ET) for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), node-positive, high risk early breast cancer (EBC). These data, which include results for investigational uses in the intent-to-treat (ITT) and Cohort 1 populations, were presented today as an oral presentation at the 2022 San Antonio Breast Cancer Symposium (SABCS) and simultaneously published in The Lancet Oncology.

Key Points: 
  • The monarchE trial (N=5,637) included women and men with HR+, HER2-, node-positive EBC with a high risk of disease recurrence.
  • Adjuvant Verzenio also reduced the risk of developing metastatic disease by 34.1% (HR=0.659, 95% CI: 0.567, 0.767; nominal p
  • Data presented at SABCS also included efficacy outcomes in the FDA-approved population, as well as the Cohort 1 population.
  • Nearly twice as many patients in the control arm have developed and are living with metastatic disease compared to those receiving Verzenio.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia, Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Big Developments Set to be Unveiled at This Year's San Antonio Breast Cancer Symposium (SABCS)

Retrieved on: 
Wednesday, November 30, 2022
MOA, NEO, HER2, Epitope, Recurrence, Chain reaction, SD, LLY, TSX, 2021 Essex County Council election, EMBER, Breast cancer classification, DNA, Poster, Radar, Circulating tumor DNA, Therapy, Health, MBA, Patient, Data, Polymerase, Eli Lilly and Company, Progression-free survival, Neoplasm, Fulvestrant, Tumor microenvironment, Eli Lilly, Research, Norwich Pharma Services, TNBC, US, PCR, ONC, G1 Therapeutics, NeoGenomics, NYSE, Oncolytics Biotech, The Monarch School, MRD, News, Woman, Breast cancer, Survival, ER, Paclitaxel, Pharmaceutical industry, Medical imaging, Vaccine, Abemaciclib, Trilaciclib

VANCOUVER, British Colombia , Nov. 30, 2022 /PRNewswire/ -- USA News Group  -  A new study has revealed that women diagnosed with benign breast disease through screening have an almost double risk of acquiring breast cancer. The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world. This year's SABCS is already shaping up to contain some big developments, including data and presentations from biotech companies such as Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), Eli Lilly and Company (NYSE: LLY), NeoGenomics, Inc. (NASDAQ: NEO), Zymeworks Inc. (NYSE: ZYME), and G1 Therapeutics, Inc. (NASDAQ: GTHX).

Key Points: 
  • The findings come ahead of this year's San Antonio Breast Cancer Symposium (SABCS), known as one of the largest breast cancer symposiums in the world .
  • The second poster will include data from a collaboration with SOLTI-Innovative Cancer Research from the AWARE-1 window-of-opportunity study in early-stage breast cancer patients.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.

Lilly Announces Details of Presentations at 2022 San Antonio Breast Cancer Symposium

Retrieved on: 
Monday, November 21, 2022
The Monarch School, Adult, Cell death, Food and Drug Administration, PI3K, Growth, Cancer, EMBER, Cyclin D1, Recurrence, Plasma, Breast, Febrile neutropenia, PIK3CA, Rb, Woman, Cell proliferation, Diarrhea, SERD, Infection, ER, Tamoxifen, Traffic barrier, CDK, Physician, Cerebrospinal fluid, Eli Lilly and Company, FDA, Breast cancer, Breast cancer classification, Phosphorylation, ESR1, ET, EBC, NYSE, OS, S phase, Hospital, Pharmacology, Patient, Molecular biology, Grade 3, Apoptosis, Toxicity, Risk, Dehydration, Cyclin-dependent kinase, Loperamide, Lilly, Retinoblastoma protein, Food, Cell cycle, Preclinical development, Grade 2, Pharmaceutical industry, Birth control, Medical imaging, Abemaciclib, Neutropenia, G1

INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.

Key Points: 
  • INDIANAPOLIS, Nov. 21, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY)today announced that study investigators will present data from its breast cancer portfolio and pipeline at the 2022 San Antonio Breast Cancer Symposium (SABCS), to be held December 6-10, 2022, in San Antonio, Texas, and virtually.
  • In addition, pharmacodynamic data from the preoperative EMBER-2 trial evaluating imlunestrant in ER+, HER2- early breast cancer will be provided.
  • Preclinical data with LOXO-783 in combination with standard-of-care breast cancer agents will also be presented at the meeting.
  • In patients with advanced cancer, including breast cancer, concentrations of Verzenio and its active metabolites (M2 and M20) in cerebrospinal fluid are comparable to unbound plasma concentrations.

Endocrine Therapy Before Surgery Results in Different Outcomes in Black vs. White Women With Breast Cancer, City of Hope-Led Study Finds

Retrieved on: 
Friday, September 16, 2022
Research, Surgery, Women, Hospitals, Clinical Trials, Health, Consumer, Science, Oncology, Science, YouTube, Lymph, Precision medicine, AACR, Woman, Twitter, Translational Genomics Research Institute, Research, Neoplasm, Organization, LinkedIn, National Cancer Institute, Hormone receptor positive breast tumor, Diabetes, Haematopoietic system, Immunotherapy, Patient, Cancer, Breast cancer, Technology, Instagram, Quality of life, Breast cancer classification, Diagnosis, Â, RNA, Conference, Mortality, City of Hope, Disease, CAR, Birth control, Medical imaging, Pharmaceutical industry, Facebook, City, Black

Black women are four times more likely than white women to die of hormone receptor-positive breast cancer.

Key Points: 
  • Black women are four times more likely than white women to die of hormone receptor-positive breast cancer.
  • While neoadjuvant endocrine therapy appeared to benefit Black women with Stage 1 and 2 breast cancer, our findings suggest that it was not beneficial in Black women with more advanced tumors.
  • To examine health outcome differences between Black and white women, Jones and colleagues analyzed 3,521 white women and 365 Black women with Stage 1 through 3 hormone receptor-positive breast cancer from the National Cancer Database.
  • Little is known about the contribution of endocrine therapy resistance to the mortality disparity seen in Black women.

Lilly Announces Details of Presentations at ESMO Congress 2022

Retrieved on: 
Wednesday, September 7, 2022
Patient, Breast cancer, Cyclin D1, Cell cycle, Technology, Food and Drug Administration, Preclinical development, S phase, Man, Recurrence, RET, Rb, EBC, Food, Transfection, CDK, Traffic barrier, Lilly, Tamoxifen, Plasma, FDA, Phosphorylation, Breast cancer classification, Adult, ET, Cell death, Cell proliferation, Cerebrospinal fluid, Woman, Growth, Apoptosis, Cyclin-dependent kinase, Retinoblastoma protein, Pharmaceutical industry, Medical imaging, Abemaciclib, G1

A Grade 3 decrease in neutrophil count (based on laboratory findings) occurred in 19 to 32% of patients receiving Verzenio.

Key Points: 
  • A Grade 3 decrease in neutrophil count (based on laboratory findings) occurred in 19 to 32% of patients receiving Verzenio.
  • Lilly unites caring with discovery to create medicines that make life better for people around the world.
  • P-LLY
    Verzenio and Retevmo are trademarks owned by or licensed toEli Lilly and Company, its subsidiaries, or affiliates.
  • Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting

Retrieved on: 
Monday, June 6, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lynx, ALT, Electrolyte, Constipation, Adult, Histology, Indigestion, Enzyme inhibitor, Antidiarrhoeal, Capecitabine, Nausea, HER3, CYP3A4, Fatigue, Abdominal pain, Food, Gastric acid, Puma Biotechnology, Arthralgia, Back pain, Dizziness, Upper respiratory tract infection, MBC, HER2, Appetite, FDA, Puma, Patient, Trastuzumab, Fetus, Kidney, Risk, Tablet, AST, Fulvestrant, Vomiting, Royal commission, Spasm, Diarrhea, Birth, Degenerative disease, Urinary tract infection, Stomatitis, European Commission, Transaminase, Rash, Fourth grade, Abdominal distension, Hepatotoxicity, Nosebleed, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Antacid, Neoplasm, Breast cancer classification, Safety, Pharmaceutical industry, Medical imaging, Vaccine

Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.

Key Points: 
  • Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.
  • We are very pleased with the updated activity seen with the combination of neratinib plus trastuzumab plus fulvestrant therapy in this heavily pretreated metastatic breast cancer patient population with HER2-mutated disease.
  • Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
  • Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.